Guggenheim analyst Vamil Divan reiterated a Buy rating and $242.00 price target on Abbvie (NYSE: ABBV).The analyst commented: "UCB (UCB.BR) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE